Renalytix Plc (LON:RENX – Get Free Report) was down 4.2% during mid-day trading on Friday . The company traded as low as GBX 1.60 and last traded at GBX 1.73. Approximately 177,778 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 986,129 shares. The stock had previously closed at GBX 1.80.
Renalytix Stock Performance
The firm has a market cap of £7.54 million, a PE ratio of -0.43 and a beta of 1.97. The company has a current ratio of 1.21, a quick ratio of 2.42 and a debt-to-equity ratio of -118.57. The firm’s 50 day simple moving average is GBX 2.23 and its 200 day simple moving average is GBX 4.68.
About Renalytix
Renalytix (LSE: RENX) (NASDAQ: RNLX) is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease, one of the most common and costly chronic medical conditions globally. The Company’s lead product is KidneyIntelX, which has been granted Breakthrough Designation by the U.S. Food and Drug Administration and which is being designed to help make significant improvements in kidney disease prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery (visit www.kidneyintelx.com).
See Also
- Five stocks we like better than Renalytix
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Renalytix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Renalytix and related companies with MarketBeat.com's FREE daily email newsletter.
